Marksans Pharma Limited has submitted the Exchange a copy Srutinizers report of Annual General Meeting held on August 08, 2025
MARKSANS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Marksans Pharma held its 33rd AGM on August 8, 2025 via video conferencing, with 261,857 shareholders on record. All 8 resolutions were passed, including adoption of FY25 financial statements, declaration of an 80% dividend (Rs. 0.80 per share on Re. 1 face value), re-appointment of Mrs. Sandra Saldanha as director, appointment of Mr. Srinivas Mishra as Independent Director for 5 years, and re-appointment of Mr. Mark Saldanha as Managing Director for another 5 years from October 6, 2025. The company also got shareholder approval to amend its ESOP 2024 scheme and extend stock options to subsidiary employees. Total voting participation was modest, with 388 members casting 24.58 crore shares (about 54.25% of outstanding shares). Most resolutions passed with near-unanimous support, though the MD re-appointment (94.01% in favour) and subsidiary ESOP grant (92.21% in favour) saw notable dissent from institutional investors.
Routine AGM outcome with no surprises; the 80% dividend is now confirmed for eligible shareholders, and promoter Mark Saldanha's continuation as MD is secured. Some institutional dissent on executive remuneration and ESOP expansion to subsidiaries is worth monitoring but is not material to operations.